Immunitybio (IBRX) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 242.6%.
| ASSET | % RETURN |
|---|---|
Immunitybio (IBRX) | 242.57% |
Alumis (ALMS) | 173.08% |
Erasca (ERAS) | 170.89% |
Critical Metals Corp Ordinary Shares (CRML) | 115.07% |
Ultra Clean (UCTT) | 80.57% |
Hycroft Mining (HYMC) | 61.35% |
Uranium Energy (UEC) | 57.49% |
USA Rare Earth (USAR) | 57.41% |
Energy Fuels (UUUU) | 53.62% |
Eos Energy Enterprises (EOSE) | 49.96% |
Vicor (VICR) | 45.42% |
FormFactor (FORM) | 44.27% |
Neogen (NEOG) | 42.42% |
Astronics (ATRO) | 39.74% |
10X Genomics (TXG) | 39.06% |
CG Oncology, Inc Common stock (CGON) | 38.7% |
Silvercorp Metals (SVM) | 38.6% |
Applied Digital (APLD) | 38.52% |
Twist Bioscience (TWST) | 37.57% |
Denison Mines (DNN) | 36.86% |
Nuscale Power (SMR) | 35.65% |
Chemours (CC) | 35.48% |
Mercury Systems (MRCY) | 35.45% |
Americas Silver (USAS) | 35.29% |
Structure Therapeutics Inc American Depositary Shares (GPCR) | 34.43% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
